GU Cancers 2020 | UC breakthroughs: personalized therapy and immunotherapies
Thanks for your feedback, this will help us improve our content for you!
Thomas Powles, MBBS, MRCP, MD, Barts Cancer Institute, London, UK, gives his thoughts on some of the biggest breakthroughs in urothelial cancer (UC). Specifically discussed is personalized therapy, immunotherapy and the evolving role of PD-L1 testing in metastatic urothelial carcinoma. This interview took place at the 2020 Genitourinary Cancers Symposium, held in San Francisco, CA.
Get great new content delivered to your inboxSign up